# Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II）

> **NCT07673835** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Obstetrics & Gynecology Hospital of Fudan University** · enrollment: 49 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **PROCEDURE:** Neoadjuvant Therapy Plus Surgery

## Key facts

- **NCT ID:** NCT07673835
- **Lead sponsor:** Obstetrics & Gynecology Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-06
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673835, "Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II）". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*